IKT – inhibikase therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Inhibikase Therapeutics GAAP EPS of -$0.65 misses by $0.17 [Seeking Alpha]
Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Activity
Inhibikase Therapeutics, Inc. (NYSE: IKT) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $8.00 price target on the stock.
Inhibikase Therapeutics Announces Closing of up to $275 Million Financing and Advancement of IkT-001Pro into a Late Stage Clinical Trial in Pulmonary Arterial Hypertension [Yahoo! Finance]
Inhibikase Therapeutics Announces Closing of up to $275 Million Financing and Advancement of IkT-001Pro into a Late Stage Clinical Trial in Pulmonary Arterial Hypertension
Form S-3 Inhibikase Therapeutics,
Form DEF 14A Inhibikase Therapeutics, For: Jan 03
Form SC 13G Inhibikase Therapeutics, Filed by: ARMISTICE CAPITAL, LLC
Form 10-Q Inhibikase Therapeutics, For: Sep 30
Form PRE 14A Inhibikase Therapeutics, For: Jan 03
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.